scholarly journals Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1330
Author(s):  
Tudor Rares Olariu ◽  
Sorin Ursoniu ◽  
Iosif Marincu ◽  
Maria Alina Lupu
Keyword(s):  
Immune Responses ◽  
Antibody Response ◽  
Healthcare Workers ◽  
Booster Dose ◽  
Time Points ◽  
Follow Up Study ◽  
Previous Infection ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Study Participants

Background and Objectives: Comprehension regarding immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is limited, and the durability of immune responses after vaccination is currently unknown. Several studies have reported on the antibody response in fully vaccinated individuals with a limited follow-up of the participants, i.e., below 7 months. Materials and Methods: The antibody response to complete vaccination with the BNT162b2 mRNA COVID-19 vaccine was assessed monthly, for 7 months, in 92 healthcare workers, between February 26 and September 26, 2021. The SARS-CoV-2 anti-spike protein IgG (IgGS) antibody was detected using the SARS-CoV-2 IgG II Quant assay (Abbott, Diagnostics Division, Sligo, Ireland), a chemiluminescent microparticle immunoassay (CMIA) with a sensitivity of 98.1% and specificity of 99.6%. Participants were divided into two groups, one for individuals previously infected with SARS-CoV-2 and the other for individuals without previous infection. Results: The median IgGS titers decreased monthly both in previously infected individuals and in the uninfected group. Previously infected individuals had significantly higher median titers of IgGS compared with previously uninfected subjects at all seven time points after complete vaccination (p < 0.001). Conclusions: Seven months after vaccination, the median IgGS titer had decreased by more than 92% both in individuals previously infected with SARS-CoV-2 and in uninfected individuals. However, IgGS antibodies were still detected in all study participants and persisted throughout the 7 months after the second dose of the vaccine. Further studies should be conducted to monitor the antibody response to the BNT162b2 mRNA vaccine beyond 7 months, to assess the need for a new booster dose in order to extend the duration and amplitude of the specific immune response.

Seven-Year Follow-Up of Screening for Hypertension and Diabetes at a Dental Clinic

2019 ◽  
Author(s):  
Göran Friman
Keyword(s):  
Antihypertensive Drugs ◽  
Study Data ◽  
Initial Screening ◽  
Pharmacological Treatments ◽  
Medical Screening ◽  
Follow Up Study ◽  
Undiagnosed Hypertension ◽  
Dental Setting ◽  
Study Participants

Objective: To describe the distribution of risk, diagnosis and pharmacological treatments for diabetes and hypertension after seven years among patients provided with opportunistic medical screening in a dental setting. Material and Methods: The initial screening’s 170 participants were asked to take part in a seven-year follow-up study. Data were collected through self-reported information in a written health declaration. Outcome measures: • Number of study participants who had passed away • Prescription of antidiabetics or antihypertensives • Changes in weight and height to calculate body mass index (BMI) Results: The follow-up study consisted of 151 participants. Twenty had passed away. The risk needs for medicating with antihypertensive drugs after seven years for those not receiving pharmacological treatment at the initial screening was 3.7 times greater (p=0.025 CI 1.2-11.3) for participants with a diastolic blood pressure (BP) ≥ 90 mm Hg (85 for diabetics) than for the others. The risk was 3.9 times greater (p=0.020 CI 1.2-12.6) for those with a systolic BP of 140-159 mm Hg and 54.2 times greater (p<0.0001 CI 9.8-300.3) for those with a systolic BP ≥ 160 mm Hg than for those with a systolic BP 140 mm Hg. There were no changes in BMI. Conclusion: At least one in ten cases of incorrect medication or undiagnosed hypertension may be identifiable through opportunistic medical screening

scholarly journals Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

2021 ◽  
Vol 10 (18) ◽  
pp. 4204
Author(s):  
Marcello Salvaggio ◽  
Federica Fusina ◽  
Filippo Albani ◽  
Maurizio Salvaggio ◽  
Rasula Beschi ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Antibody Concentration ◽  
Clinical Documentation ◽  
Receptor Binding Domain ◽  
Effective Number ◽  
Significant Difference ◽  
Before And After ◽  
Previous Infection ◽  
Antibody Levels

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to asymptomatic previously exposed subjects. The aim of this study is to assess if any difference in antibody concentration between subjects exposed and not exposed to SARS-CoV-2 prior to BNT162b2 was present after the first dose and after the second dose of vaccine. Data were retrospectively collected from the clinical documentation of 337 healthcare workers who underwent SARS-CoV-2 testing before and after BNT162b2. Total anti RBD (receptor-binding domain) antibodies against SARS-CoV-2′s spike protein were measured before and 21 days after the first dose, and 12 days after the second dose of BNT162b2. Twenty-one days after the first dose, there was a statistically significant difference in antibody concentration between the two groups, which was also maintained twelve days after the second dose. In conclusion, antibody response after receiving BNT162b2 is greater in subjects who have been previously exposed to SARS-CoV-2 than in subjects who have not been previously exposed to the virus, both after 21 days after the first dose and after 12 days from the second dose. Antibody levels, 21 days after the first dose, reached a titer considered positive by the test manufacturer in the majority of subjects who have been previously infected with SARS-CoV-2. Evaluating previous infection prior to vaccination in order to give the least effective number of doses should be considered.

scholarly journals Persistence of Fatigue among COVID-19 Survivors in Bangladesh: A Two-month after Follow-up Study

2021 ◽  
Vol 33 (1) ◽  
pp. 57-63
Author(s):  
Md Khairul Islam ◽  
Mohammad Murad Hossain ◽  
Md Monowar Hossain ◽  
Md Mohiuddin Sharif ◽  
Fahima Sharmin Hossain ◽  
...  
Keyword(s):  
Logistic Regression Model ◽  
Telephone Interview ◽  
Binary Logistic Regression ◽  
Binary Logistic Regression Model ◽  
Follow Up Study ◽  
Laboratory Markers ◽  
Study Participants ◽  
Prevalent Symptom ◽  
D Dimer

Background: A limited number of studies have exclusively assessed fatigue among post-COVID patients. Our study aimed to assess the persistence and associations of fatigue among COVID-19 survivors after two months of recovery from their primary illness. Methods: During hospital admission from August to September, 2020, a total of 400 patients were diagnosed to be suffering from fatigue using Chalder fatigue scale. After obtaining informed written consent, patients were followed up two months later over telephone. A total of 332 participants participated in the interview (63 patients could not be traced and another 5 patient died within two months). Patients were asked to categorize their present fatigue condition based on a simplified questionnaire developed for telephone interview. Results: Among study participants, 62.9% (n=207) were found to be still suffering from fatigue two months after their hospital discharge. A significant association of fatigue was found with age (p=0.000), hypertension (RR: 1.51; CI: 1.15-1.99; p=0.002), diabetes mellitus (RR: 1.45; CI: 1.08-1.95; p=0.010), ischemic heart disease (RR: 2.04; CI: 1.15-3.64; p=0.011), on admission SpO2 (p=0.000), on admission serum ferritin (p=0.000), d-dimer (p=0.000), CRP (p=0.000), and Hb% (p=0.019). Binary logistic regression model revealed significant association of age and onadmission SpO2 with persistence of fatigue. Conclusions: Fatigue is a highly prevalent symptom among the COVID-19 survivors with significant association between fatigue and patients clinical and laboratory markers. Bangladesh J Medicine July 2022; 33(1) : 57-63

scholarly journals A follow-up study of the human class and subclass antibody response developed against the adult stage ofTrichinella spiralis

Parasite ◽  
2001 ◽  
Vol 8 ◽  
pp. S163-S167 ◽  
Author(s):  
M.R. Chapa-Ruiz ◽  
D. González-Pantaleón ◽  
A. Morales-Galán ◽  
A. Contreras-Ramos ◽  
M. Salinas-Tobón ◽  
...  
Keyword(s):  
Antibody Response ◽  
Adult Stage ◽  
Human Class ◽  
Follow Up Study
Sign in / Sign up

Export Citation Format

Share Document